PR89333

SEOUL, South Korea, May 7, 2021 /PRNewswire=KYODO JBN/ --

Has significantly reduced side effects of the current diabetes drugs on the

market

Maximize effectiveness by reducing drug and insulin resistance from long-term

use

Nexturn Bio Inc., a subsidiary of Nexturn Bioscience Co., Ltd. (KOSDAQ:89140),

said it has secured a 50% stake in RosVivo Therapeutics Inc., a U.S. new drug

developer, as its first investment destination. RosVivo recently developed

RSVI-301, a new drug pipeline that utilizes miRNA (MicroRNA), which is expected

to be the next-generation drug, following mRNA (Messenger RNA), which has

attracted attention as a Covid-19 vaccine. Unlike rare diseases or cancer,

targeting chronic disease "diabetes," seems to have positively affected Nexturn

Bio's investment.

According to data released by the WHO in April this year, the number of

diabetes patients worldwide is about 420 million, which has maintained a high

prevalence rate until recently. The figure of the patients proves that diabetes

drugs currently developed up to the fourth generation are not as effective as

expected. In fact, Liraglutide, which are known to be the most effective

component of diabetes drugs ever approved by the FDA, have also reported

vomiting, diarrhea, constipation and indigestion as side effects from the

clinical stages. The side effect reduction of RSVI-301 is more noticeable in

the table below, compiled according to the research paper provided by RosVivo.

(figure 1).

Furthermore, it has been observed that RSVI-301 reduces insulin resistance by

normal levels during repeated drug infusions (figure 2). With the result of

being completely opposite to the existing diabetes drugs, the possibility of

overcoming insulin resistance raises RSVI-301 expectations in the related

industry. The low side effects and the long-term lasting effects of RSVI-301

are expected to play a major competitive role in the future diabetes market in

regard to patient convenience. An official from Nexturn Bio Inc. added, "We

will continue to provide generous support for RosVivo's development of new

drugs as well as to cure diabetes together."

SOURCE NEXTURN Bio Inc.

Image Attachments Links:

   Link: http://asianetnews.net/view-attachment?attach-id=390537

   Caption: Rosvivo’s new miRNA treatment RSV1-301 vs. diabetes drug on the market

   Link: http://asianetnews.net/view-attachment?attach-id=390647

   Caption: Insulin resistance and secretion changes after injection of the new drug miRNA